Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN)

Vaccine

Volumn 20, Issue 27-28, 2002, Pages 3277-3284

  Borja Cabrera, G P ^a   Correia Pontes, N N ^a   Da Silva, V O ^a   Paraguai De Souza, E ^a   Santos, W R ^a   Gomes, E M ^a   Luz, K G ^b   Palatnik, M ^a   Palatnik De Sousa, C B ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Canine visceral leishmaniasis; Kala azar; Leishmania donovani; Phase III trial; Zoonoses

Indexed keywords

FUCOSE MANNOSE LIGAND QUIL A VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BRAZIL; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; LEISHMANIA DONOVANI; LEISHMANIASIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; VACCINATION;

EID: 0037055992     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00294-3     Document Type: Article

References (37)

1. Tesh R. Control of zoonotic visceral leishmaniasis, is it time to change strategies? Am. J. Trop. Med. Hyg. 52:1995;287-292.
2. Palatnik-de-Sousa C.B., Santos W.R., França-Silva J.C., Costa R.T., Barbosa Reis A., Palatnik M.et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 65:2001;510-517.
3. Ashford D.A., David J.R., Freire M., David R., Sherlock I., Eulálio M.C.et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am. J. Trop. Med. Hyg. 59:1998;53-57.
4. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 55:1996;125-130.
5. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M.et al. A phase III trial of efficacy of the FML vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine. 19:2001;1082-1092.
6. Lasri S., Sahibi H., Sadak A., Jaffe C.L., Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet. Res. 30:1999;441-449.
7. Dunan S., Frommel D., Monjour L., Ogunkolade B.W., Cruz A., Quilici M. Vaccination trial against canine visceral leishmaniasis. Parasite Immunol. 11:1989;397-402.
8. Antunes C.M., Mayrink W., Magalhães P.A., Costa A., Melo M.N., Dias M.et al. Controlled field trials of a vaccine against new world cutaneous leishmaniasis. Int. J. Epidemiol. 15:1986;572-580.
9. Mayrink W., Genaro O., Franca-Silva J.C., Costa R.T., Tafuri L., Toledo V.P.C.P.et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem. Inst. Osw. Cruz MEMIOC. 91:1996;695-697.
10. Genaro O., Pinto J.A., da Costa C.A., França Silva J.C., Costa R.T., Silva J.C.et al. Phase III randomized double blind clinical trial of the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil. Mem. Inst. Osw. Cruz MEMIOC. 91:1996;166.
11. Palatnik de Sousa C.B., Paraguai de Souza E., Gomes E.M., Borojevic R. Experimental murine Leishmania donovani infection immunoprotection by the fucose mannose ligand (FML). Braz. J. Med. Biol. Res. 27:1994;547-551.
12. Santos W.R., Paraguai de Souza E., Palatnik M., Palatnik de Sousa C.B. Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model. Vaccine. 17:1999;2554-2561.
13. Palatnik de Sousa C.B., Moreno M.B., Paraguai de Souza E., Borojevic R. The FML vaccine (fucose mannose ligand) protects hamsters from experimental kala-azar. Ciência e Cultura (J. Braz. Assoc. Adv. Sci.). 46:1994;290-296.
14. Palatnik C.B., Borojevic R., Previato J.O., Mendonça-Previato L. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate. Infect. Immun. 57:1989;754-763.
15. Palatnik de Sousa C.B., Dutra H.S., Borojevic R. Leishmania donovani surface glycoconjugate gp36 is the major immunogen component of the fucose mannose ligand (FML). Acta Trop. 53:1993;59-72.
16. Palatnik de Sousa C.B., Gomes E.M., Paraguai de Souza E., Luz K., Palatnik M., Borojevic R. Leishmania donovani: titration of antibodies to the fucose mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg. 89:1995;390-393.
17. Borja Cabrera G.P., da Silva V.O., da Costa R.T., Barbosa Reis A., Mayrink W., Genaro O.et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am. J. Trop. Med. Hyg. 61:1999;296-301.
18. Schetters T.P.M., Kleuskens J., Scholtes N., Bos H.J. Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture. Parasite Immunol. 14:1992;295-305.
19. Bomford R., Stapleton M., Winsor S., Mc Night A., Andronova T. The control of the antibody isotype response to recombinant immunodeficiency virus gp120 antigen by adjuvants. AIDS Res. Hum. Retrovir. 8:1992;1765-1771.
20. Sjolander S., Hansen J.E., Lovgren-Bengtsson K., Akerblom L., Morein B. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations: a comparison with other adjuvant systems. Vaccine. 14:1996;344-352.
21. Cox S.J., Barnett P.V., Dani P., Salt J.S. Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine. 17:1999;1858-1868.
22. Rikihisha Y. Protection against murine Potomac horse fever by an inactivated Erlichia risticii vaccine. Vet. Microbiol. 27:1991;339-350.
23. Chang Y.F., Appel M.J., Jacobson R.H., Shin S.J., Harpending P., Straubinger R.et al. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect. Immun. 63:1995;3543-3549.
24. Flies JL. Statistical Methods for Rates and Proportions. New York: Wiley, 1973. p. 190.
25. Paranhos-Silva M., Freitas L.A., Santos W.C., Grimaldi G. Jr., Pontes de Carvalho L., Oliveira dos Santos A. A cross-sectional serodiagnostic survey of canine leishmaniasis due to Leishmania chagasi. Am. J. Trop. Med. Hyg. 55:1996;39-44.
26. WHO. Guidelines for the Evaluation of Plasmodium Falciparum in Populations Exposed to Natural Infection. WHO/TDR/MAL/VAC/97, 1997. p. 24.
27. Genaro O., Raso P., da Costa C.A., Duarte-Carvalho M., do Amaral F., de Carvalho-Botelho A.C.et al. Montenegro skin test in dogs experimentally infected with Leishmania Viannia brasiliensis. Mem. Inst. Osw. Cruz (MEMIOC). 87:1992;163-164.
28. Pinelli E., Killick-Kendrick R., Wagennar E., Barnadina W., del Real G., Ruitenberg J. Cellular and humoral immune responses in dogs experimentally and naturally infects with Leishmania (L) infantum. Inf. Immunol. 62:1994;229-235.
29. Cardoso L., Nieto F., Souza J.C., Rodrigues M., Cabral M. Use of a leishmanin skin test in the detection of canine leishmanin-specific cellular immunity. Vet. Parasitol. 79:1998;213-220.
30. De Luca PM, Mayrink W, Pinto JÁ, Coutinho SG, Santiago MA, Toledo VP, et al. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Trp 2001;251-60.
31. Borja Cabrera GP. Análise do Potencial Diagnóstico, Prognóstico e Imunoprotetor do Antígeno FML (Ligante de Fucose Manose) de Leishmania (L) Donovani, no Calazar Canino Experimental e de Área Endêmica. Ph.D. Thesis. Post-graduate program in experimental pathology, Federal Fluminense University. (Rio de Janeiro) Brazil: Niteroi, 2000.
32. Cruz Mendes A, Borja Cabrera GP, Paraguai de Souza E, Santos WR, Gomes EM, Palatnik de Sousa CB. Immunoteraphy against canine kala-azar with the FML antigen of Leishmania (L) donovani and the QuilA saponin. In: Proceedings of the Abstracts of the 5th Meeting on Applied Research in Leishmaniasis, Uberaba, MG, Brazil, 2001. p. 80-1.
33. Solano-Gallego L, Llul J, Ramos G, Riera C, Arboix M, Alberola J, et al. The Ibizian hound presents a predominanttly cellular immune response against natural Leishmania infection. Vet Parasitol 2000;37-45.
34. Khalil EAG, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa Breyma, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomized, double blind, BCG-controlled trial in Sudan. Lancet, 2000;356:1565-9.
35. Deplazes P., Smith N.C., Arnold P., Lutz H., Eckert J. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol. 17:1995;451-458.
36. Nieto C.G., Garcia Alonso M., Requena J.M., Miron C., Soto M., Alonso C.et al. Analysis of the humoral response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet. Immunol. Immunopathol. 67:1999;117-130.
37. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Peribanez M.A., Alvar J.et al. Canine leishmaniasis transmission: higher infectivity among naturally infected dogs to sandflies is associated with lower proportions of T helper cells. Res. Vet. Sci. 69:2000;249-253.